重度高甘油三血症药物治疗的最新情况
Ioanna Gouni-Berthold1, Jonas Schwarz2, Heiner K Berthold3
1Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital, Kerpener Str. 6, 50937, Cologne, Germany. ioanna.berthold@uni-koeln.de.
Current atherosclerosis reports
|August 29, 2023
概括
像反感性寡核酸和siRNA这样的新疗法对严重的高甘油三血症 (sHTG) 是有前途的. 然而,最终降低急性胰腺炎风险仍然是所有治疗方法的挑战.
科学领域:
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
- 内部医学 内部医学
背景情况:
- 严重的高甘油三血症 (sHTG) 带来了重大治疗挑战.
- 传统疗法在降低甘油三和预防急性胰腺炎 (AP) 的有效性有限.
研究的目的:
- 审查严重高甘油三血症 (sHTG) 的新兴药物治疗方法.
- 评估针对APOC3和ANGPTL3的新型治疗剂.
主要方法:
- 关于新药药理学剂的最新临床发现的审查.
- 讨论反感性寡核酸 (ASO) 和小干扰RNA (siRNA) 疗法.
- 对sHTG的批准和试验药物的分析.
主要成果:
- 伏拉尼索森 (ASO) 在欧洲已获批准用于家族性胆小血症综合征 (FCS).
- 奥莱扎森 (ASO) 显示出潜在的改善的安全性和有效性.
- 在sHTG治疗中,ARO-APOC3和ARO-ANG3 (siRNA) 是有前途的.
- 埃维纳库马布和vupanorsen被放弃用于sHTG治疗.
结论:
- 新的ASO和siRNA疗法为管理sHTG提供了新的途径.
- 减少急性胰腺炎 (AP) 风险,这是主要的临床目标,目前的或正在研究的药物疗法尚未最终实现.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
697
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
697
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
213
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
213
Hypertension IV: Drug Therapy and Lifestyle Modifications
13
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
13
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
186
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
186


